search
Back to results

Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures

Primary Purpose

Tibial Fracture

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
CERAMENT|G
SOC treatment
Sponsored by
BONESUPPORT AB
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tibial Fracture focused on measuring wound, open fracture, fracture, tibial

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers
  1. Male or female 18-21 years of age with radiographic evidence on plain x-rays of proximal and distal tibial physeal closure, OR male or female 22-75 years of age
  2. Gustilo-Anderson Grade II, IIIA, or IIIB open tibial shaft fracture (with or without involvement of the tibial plateau or pilon/plafond) amenable to fixation with an intramedullary nail
  3. Bone loss at the fracture site must have a radiographic apparent bone gap (RABG) between 3 and 27.5 millimeters.
  4. Life expectancy of at least 1 year
  5. Patient is willing to provide informed consent, is geographically stable and able to comply with the required follow up visits, testing schedule and medication regimen
  6. Adequate soft tissue coverage at the fracture site (through primary closure or surgical reconstruction, including local and free soft tissue transfer)
  7. Definitive wound closure within 14 days of the initial injury
  8. Unilateral fracture, or, in the case of individually-qualifying bilateral open tibia fractures, the more severe of the bilateral fractures.

Patients will be excluded if ANY of the following conditions apply:

  1. Pregnant or breastfeeding women or planning on becoming pregnant during the investigational period
  2. Patient is currently participating in an investigational drug or other device study or previously enrolled in this study
  3. Renal failure or documented chronic kidney disease with serum creatinine ≥3.5 mg/L or being treated with dialysis
  4. Known hypersensitivity to aminoglycoside antibiotics, calcium sulfate or calcium hydroxyapatite
  5. Pre-existing calcium metabolism disorder
  6. Uncontrolled diabetes mellitus (hemoglobin A1c levels > 10%)
  7. A current endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, hyperthyroidism, parathyroid hormone disorder, Ehler-Danlos syndrome, osteogenesis imperfecta)
  8. Neuromuscular disorders such as myasthenia gravis or Parkinson's disease
  9. Currently has untreated malignant neoplasm(s), or is currently undergoing radiation therapy or chemotherapy
  10. Previous history of osteomyelitis in the index limb
  11. Ipsilateral tibial plateau or pilon/plafond fractures requiring a reconstruction that interferes with or prohibits the use of an intramedullary nail to stabilize the tibial shaft fracture or, in the opinion of the investigator, the treatment and/or rehabilitation of such fracture(s) would substantially interfere with the treatment, rehabilitation or other requirements of open tibial shaft fractures enrolled under this protocol.
  12. Other ipsilateral lower extremity fracture(s) if, in the opinion of the investigator, the treatment and/or rehabilitation of such fracture(s) will substantially interfere with the treatment, rehabilitation or other requirements outlined in this protocol.

Sites / Locations

  • University of Alabama at Birmingham
  • University of California
  • University of Southern California
  • Cedars Sinai Medical Orthopedic
  • Harbor-UCLA Medical Center
  • Denver Health Medical Center
  • University of Chicago
  • University of Kentucky
  • University of Missouri Health
  • Washington University
  • University of New Mexico
  • New York University, Bellevue Hospital
  • University of Cincinnati
  • Department of Orthopedics Greenville Health System
  • Vanderbilt University Medical Center
  • University of Texas Health Science Center
  • West Virginia University
  • Klinikum Bayreuth
  • Essen University Hospital
  • BG Hospital Ludwigshafen
  • Universitätsmedizin Mainz
  • Rechts der Isar Hospital
  • LMU Munich
  • Universitätsklinikum Regensburg
  • Samodzielny Publiczny Wojewodzki Szpital
  • University Hospital Coventry
  • The Royal London Hospital
  • King's College Hospital
  • Imperial College
  • University Hospitals
  • Southampton General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Test

Control

Arm Description

Tibial fracture fixation with IM Nail. Apply CERAMENT™|G applied to bony void(s).

Tibial fracture fixation with IM nail.

Outcomes

Primary Outcome Measures

Composite of absence of deep infection at fracture site, absence of secondary procedures intended to promote fracture union, and improvement in the SF-36v2 PCS.
Absence of secondary procedures, absence of infection.
Serious device related adverse events
for the test (CERAMENT™|G) arm

Secondary Outcome Measures

Full Information

First Posted
June 27, 2016
Last Updated
August 6, 2021
Sponsor
BONESUPPORT AB
search

1. Study Identification

Unique Protocol Identification Number
NCT02820363
Brief Title
Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures
Official Title
A Prospective, Randomized Multicenter Controlled Trial of CERAMENT™|G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
February 14, 2017 (Actual)
Primary Completion Date
July 31, 2021 (Actual)
Study Completion Date
July 31, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BONESUPPORT AB

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to demonstrate the safety and effectiveness of CERAMENT™|G used in conjunction with standard-of-care treatment compared to standard-of-care treatment alone in the care of subjects with open fractures of the tibial diaphysis.
Detailed Description
CERAMENT™|G is a resorbable, gentamicin containing ceramic bone graft indicated to fill bony voids or gaps which are not intrinsic to the stability of the bony structure and where there is risk of bacterial contamination.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tibial Fracture
Keywords
wound, open fracture, fracture, tibial

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
201 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Test
Arm Type
Experimental
Arm Description
Tibial fracture fixation with IM Nail. Apply CERAMENT™|G applied to bony void(s).
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Tibial fracture fixation with IM nail.
Intervention Type
Device
Intervention Name(s)
CERAMENT|G
Intervention Description
Surgical repair of tibia fracture, CERAMENT™|G applied to bony voids.
Intervention Type
Procedure
Intervention Name(s)
SOC treatment
Intervention Description
surgical repair of tibial fracture
Primary Outcome Measure Information:
Title
Composite of absence of deep infection at fracture site, absence of secondary procedures intended to promote fracture union, and improvement in the SF-36v2 PCS.
Description
Absence of secondary procedures, absence of infection.
Time Frame
12 months
Title
Serious device related adverse events
Description
for the test (CERAMENT™|G) arm
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Male or female 18-21 years of age with radiographic evidence on plain x-rays of proximal and distal tibial physeal closure, OR male or female 22-75 years of age Gustilo-Anderson Grade II, IIIA, or IIIB open tibial shaft fracture (with or without involvement of the tibial plateau or pilon/plafond) amenable to fixation with an intramedullary nail Bone loss at the fracture site must have a radiographic apparent bone gap (RABG) between 3 and 27.5 millimeters. Life expectancy of at least 1 year Patient is willing to provide informed consent, is geographically stable and able to comply with the required follow up visits, testing schedule and medication regimen Adequate soft tissue coverage at the fracture site (through primary closure or surgical reconstruction, including local and free soft tissue transfer) Definitive wound closure within 14 days of the initial injury Unilateral fracture, or, in the case of individually-qualifying bilateral open tibia fractures, the more severe of the bilateral fractures. Patients will be excluded if ANY of the following conditions apply: Pregnant or breastfeeding women or planning on becoming pregnant during the investigational period Patient is currently participating in an investigational drug or other device study or previously enrolled in this study Renal failure or documented chronic kidney disease with serum creatinine ≥3.5 mg/L or being treated with dialysis Known hypersensitivity to aminoglycoside antibiotics, calcium sulfate or calcium hydroxyapatite Pre-existing calcium metabolism disorder Uncontrolled diabetes mellitus (hemoglobin A1c levels > 10%) A current endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, hyperthyroidism, parathyroid hormone disorder, Ehler-Danlos syndrome, osteogenesis imperfecta) Neuromuscular disorders such as myasthenia gravis or Parkinson's disease Currently has untreated malignant neoplasm(s), or is currently undergoing radiation therapy or chemotherapy Previous history of osteomyelitis in the index limb Ipsilateral tibial plateau or pilon/plafond fractures requiring a reconstruction that interferes with or prohibits the use of an intramedullary nail to stabilize the tibial shaft fracture or, in the opinion of the investigator, the treatment and/or rehabilitation of such fracture(s) would substantially interfere with the treatment, rehabilitation or other requirements of open tibial shaft fractures enrolled under this protocol. Other ipsilateral lower extremity fracture(s) if, in the opinion of the investigator, the treatment and/or rehabilitation of such fracture(s) will substantially interfere with the treatment, rehabilitation or other requirements outlined in this protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Douglas R. Dirschl, MD
Organizational Affiliation
The University of Chicago Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294-3409
Country
United States
Facility Name
University of California
City
Irvine
State/Province
California
ZIP/Postal Code
62697
Country
United States
Facility Name
University of Southern California
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
Cedars Sinai Medical Orthopedic
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Harbor-UCLA Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90509
Country
United States
Facility Name
Denver Health Medical Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80204
Country
United States
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
University of Kentucky
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States
Facility Name
University of Missouri Health
City
Columbia
State/Province
Missouri
ZIP/Postal Code
65212
Country
United States
Facility Name
Washington University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
University of New Mexico
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87106
Country
United States
Facility Name
New York University, Bellevue Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
University of Cincinnati
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267-0212
Country
United States
Facility Name
Department of Orthopedics Greenville Health System
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29605
Country
United States
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Facility Name
University of Texas Health Science Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
West Virginia University
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26506
Country
United States
Facility Name
Klinikum Bayreuth
City
Bayreuth
ZIP/Postal Code
DE-95445
Country
Germany
Facility Name
Essen University Hospital
City
Essen
ZIP/Postal Code
45147
Country
Germany
Facility Name
BG Hospital Ludwigshafen
City
Ludwigshafen
ZIP/Postal Code
67071
Country
Germany
Facility Name
Universitätsmedizin Mainz
City
Mainz
Country
Germany
Facility Name
Rechts der Isar Hospital
City
Munich
ZIP/Postal Code
81675
Country
Germany
Facility Name
LMU Munich
City
Munich
Country
Germany
Facility Name
Universitätsklinikum Regensburg
City
Regensburg
Country
Germany
Facility Name
Samodzielny Publiczny Wojewodzki Szpital
City
Szczecin
ZIP/Postal Code
70-891
Country
Poland
Facility Name
University Hospital Coventry
City
Coventry
ZIP/Postal Code
CV 2 2DX
Country
United Kingdom
Facility Name
The Royal London Hospital
City
London
ZIP/Postal Code
E1BB
Country
United Kingdom
Facility Name
King's College Hospital
City
London
ZIP/Postal Code
SE5 9R
Country
United Kingdom
Facility Name
Imperial College
City
London
Country
United Kingdom
Facility Name
University Hospitals
City
Manchester
ZIP/Postal Code
M23 9LT
Country
United Kingdom
Facility Name
Southampton General Hospital
City
Southampton
ZIP/Postal Code
SO16 6YD
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures

We'll reach out to this number within 24 hrs